Indication for allogeneic stem cell transplantation in Glanzmann’s thrombasthenia

V. Wiegering; K. Sauer; B. Winkler; M. Eyrich; P. G. Schlegel

doi:10.5482/HAMO-12-08-0014

Hämostaseologie, Table of Contents

Hamostaseologie 2013; 33(04): 305-312
DOI: 10.5482/HAMO-12-08-0014

Review

Schattauer GmbH

Indication for allogeneic stem cell transplantation in Glanzmann’s thrombasthenia

Indikationen zur allogenen Stammzelltransplation bei Patienten mit Thrombasthenia Glanzmann

V. Wiegering

¹Department of Paediatric Haematology, Oncology, Paediatric Stem Cell Transplant Program, University Children’s Hospital Würzburg, Germany

,

K. Sauer

² Institute of Clinical Biochemistry and Pathobiochemistry-Central Laboratory, University of Würzburg, Germany

,

B. Winkler

¹Department of Paediatric Haematology, Oncology, Paediatric Stem Cell Transplant Program, University Children’s Hospital Würzburg, Germany

,

M. Eyrich

¹Department of Paediatric Haematology, Oncology, Paediatric Stem Cell Transplant Program, University Children’s Hospital Würzburg, Germany

,

P. G. Schlegel

¹Department of Paediatric Haematology, Oncology, Paediatric Stem Cell Transplant Program, University Children’s Hospital Würzburg, Germany

› Author Affiliations

Abstract

Summary

Glanzmann’s thrombasthenia (GT) is an autosomal recessive disorder characterized by a lack of thrombocyte aggregation due to the absence of thrombocyte glycoproteins IIb and αIIbβ3. The role of haematopoietic stem cell transplantation (HSCT) in GT remains controversial. However, HSCT offers the only curative approach for patients with a severe clinical phenotype.

In this review, we will discuss the limitation of current status evidence and the specific risk of GT, in particular the alloimmunization and refractoriness to thrombocyte infusions. 19 successful HSCT in 18 GT type I patients have been reported. Mean age at transplantation was 5 years. All patients are still alive. The majority received sibling bone marrow transplant with busulfan and cyclophosphamid conditioning. GvHD incidence was within the normal range, but 10 patients showed alloimmunization of thrombocytes. Median follow up is 25 months.

Zusammenfassung

Die Thrombasthenia Glanzmann (GT) ist eine autosomal rezessive Erkrankung, bei der die Thrombozytenaggregation durch einen fehlenden bzw. funktionell inaktiven Glykoprotein-αIIbβ3-Komplex stark vermindert ist. Die allogene Stammzelltransplantation (HSCT) stellt bei Patienten mit einem schweren Phänotyp die einzige kurative Therapieoption dar. Ihre Indikation wird kontrovers gesehen. In dieser Übersicht werden Datenlage und spezifische Risiken bei GT diskutiert, insbesondere das Auftreten von Alloimmunisation und Refraktivität gegenüber Thrombozytenkonzentraten. Über 19 HSCT bei 18 GT-Typ-1-Patienten wurde in der Literatur berichtet. Das mittlere Alter bei Transplantation lag bei fünf Jahren. Der Mehrheit wurde Knochenmark eines HLA-identen Geschwisters transplantiert nach Konditionierung mit Busulfan und Cyclophosphamid. Die GvHD-Inzidenz lag im durchschnittlichen Bereich, jedoch trat bei zehn GT-Patienten eine Alloimmunisation in Bezug auf Thrombozyten auf. Die durchschnittliche Nachbeobachtungszeit liegt bei 25 Monaten.

Keywords

Glanzmann thrombasthenia - allogeneic stem cell transplantation - alloimmunization

Schlüsselwörter

Thrombasthenia Glanzmann - allogene Stammzelltransplantation - Alloimmunisation

Full Text

References

References
1 Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006 01. 10.
2 Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112: 3011-3025.
3 French DL. The molecular genetics of Glanzmann’s thrombasthenia. Platelets 1998; 09: 5-20.
4 Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010; 411: 1-6.
5 George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-1395.
6 Rosas RR, Kurth MH, Sidman J. Treatment and outcomes for epistaxis in children with Glanzmann’s thrombasthenia. Laryngoscope 2010; 120: 2374-2377.
7 Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118: 5996-6005.
8 Nurden AT, Pillois X, Fiore M. et al. Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the alphaIIbbeta3 integrin. Semin Thromb Hemost 2011; 37: 698-706.
9 Kannan M, Saxena R. Glanzmann’s thrombasthenia: an overview. Clin Appl Thromb Hemost 2009; 15: 152-165.
10 Poon MC, d’Oiron R, Hann I. et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 2001; 38 (4 Suppl 12) 21-25.
11 Perutelli P, Marchese P, Mori PG. Diagnosis of Glanzmann’s thrombasthenia and carrier detection using monoclonal antibodies to platelet glycoprotein IIb and IIIa in immunoblotting. Haemostasis 1992; 22: 330-333.
12 Perutelli P, Mori PG. Biochemical and molecular basis of Glanzmann’s thrombasthenia. Haematologica 1992; 77: 421-426.
13 Bellucci S, Caen J. Molecular basis of Glanzmann’s thrombasthenia and current strategies in treatment. Blood Rev 2002; 16: 193-202.
14 Santoro C, Rago A, Biondo F. et al. Prevalence of allo-immunization anti-HLA and anti-integrin alpha IIbbeta3 in Glanzmann Thromboasthenia patients. Haemophilia 2010; 16: 805-812.
15 Bolan CD, Alving BM. Pharmacological Agents in the Management of Bleeding Disorders. Transfusion 1990; 30: 541-551.
16 Poon MC, D’Oiron R, Von Depka M. et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost 2004; 02: 1096-1103.
17 Bellucci S, Devergie A, Gluckman E. et al. Complete correction of Glanzmann’s thrombasthenia by allogeneic bone-marrow transplantation. Br J Haematol 1985; 59: 635-641.
18 Tichelli A, Rovo A, Passweg J. et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol 2009; 02: 583-601.
19 Baker KS, Bresters D, Sande JE. The burden of cure: long-term side effects following hematopoietic stem cell transplantation in children. Pediatr Clin North Am 2010; 57: 323-342.
20 Baker KS, Armenian S, Bhatia S. Long-term consequences of hematopoietic stem cell transplantation: current state of the science. Biol Blood Marrow Transplant 2010; 16 (Suppl. 01) S90-S96.
21 Gaziev D, Polchi P, Galimberti M. et al. Graft-versus-host disease after bone marrow transplantation for thalassemia – An analysis of incidence and risk factors. Transplantation 1997; 63: 854-860.
22 Walters MC, Storb R, Patience M. et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95: 1918-1924.
23 Little AM. An overview of HLA typing for hematopoietic stem cell transplantation. Methods Mol Med 2007; 134: 35-49.
24 Korbling M, Freireich EJ. 25 years of peripheral blood stem cell transplantation. Blood 2011; 117: 6411-6416.
25 Lang P, Handgretinger R, Greil J. et al. Transplantation of CD34+ enriched allografts in children with nonmalignant diseases: does graft manipulation necessarily result in high incidence of graft failure?. Bone Marrow Transplant 2004; 33: 125-126.
26 D’Andrea G, Margaglione M. Glanzmann’s thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism. Haematologica 2003; 88: 1378-1382.
27 Ghosh K, Kulkarni B, Nair S. et al. Human platelet alloantigen polymorphism in Glanzmann’s thrombasthenia and its impact on the severity of the disease. Br J Haematol 2002; 119: 348-353.
28 Di Minno G, Coppola A, Di Minno MN, Poon MC. Glanzmann’s thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009; 102: 1157-1164.
29 Johnson A, Goodall AH, Downie CJ. et al. Bone marrow transplantation for Glanzmann’s thrombasthenia. Bone Marrow Transplant 1994; 14: 147-150.
30 Wiegering V, Winkler B, Langhammer F. et al. Allogeneic Hematopoietic Stem Cell Transplantation in Glanzmann Thrombasthenia Complicated by Platelet Alloimmunization. Klin Padiatr 2011; 223: 173-175.
31 Jacobin MJ, Laroche-Traineau J, Little M. et al. Human IgG monoclonal anti-alpha(IIb)beta(3)-binding fragments derived from immunized donors using phage display. J Immunol 2002; 168: 2035-2045.
32 Martin I, Kriaa F, Proulle V. et al. Protein A sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann’s thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol 2002; 119: 991-997.
33 Connor P, Khair K, Liesner R, Amrolia P, Veys P, Ancliff P. et al. Stem cell transplantation for children with Glanzmann thrombasthenia. Br J Haematol 2008; 140: 568-571.
34 Flood VH, Johnson FL, Boshkov LK. et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer 2005; 45: 971-975.
35 Ishaqi MK, El-Hayek M, Gassas A. et al. Allogeneic stem cell transplantation for Glanzmann thrombasthenia. Pediatr Blood Cancer 2009; 52: 682-683.
36 Kitko CL, Levine JE, Matthews DC, Carpenter PA. Successful unrelated donor cord blood transplantation for Glanzmann’s thrombasthenia. Pediatr Transplant 2011; 15: e42-e46.
37 Solh M, Mescher C, Klappa A. et al. Acquired Glanzmann’s thrombasthenia with optimal response to rituximab therapy. Am J Hematol 2011; 86: 715-716.
38 Bolton-Maggs PH, Chalmers EA, Collins PW. et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-633.
39 Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
40 Tarantino MD, Goldsmith G. Treatment of acute immune thrombocytopenic purpura. Semin Hematol 1998; 35 (1 Suppl 1) 28-35.
41 Tomaske M, Bosk A, Eyrich M. et al. Risks of mortality in children admitted to the paediatric intensive care unit after haematopoietic stem cell transplantation. Br J Haematol 2003; 121: 886-891.
42 Bougie DW, Wilker PR, Wuitschick ED. et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100: 2071-2076.
43 Miller W, Dunn A, Chiang KY. Sustained engraftment and resolution of bleeding phenotype after unrelated cord blood hematopoietic stem cell transplantation for severe glanzmann thrombasthenia. J Pediatr Hematol Oncol 2009; 31: 437-439.
44 Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477-481.
45 Alamelu J, Liesner R. Modern management of severe platelet function disorders. Br J Haematol 2010; 149: 813-823.
46 Seligsohn U. Treatment of inherited platelet disorders. Haemophilia 2012; 18 (Suppl. 04) 161-165.
47 Mousa SA, Forsythe MS. Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography. Thromb Res 2001; 104: 49-56.
48 Lison S, Spannagl M, Heindl B. Perioperative haemostatic management of Glanzmann thrombasthenia for abdominal surgery. Blood Coagul Fibrinolysis 2009; 20: 371-373.
49 Fujimoto TT, Kishimoto M, Ide K. et al. Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation. Int J Hematol 2005; 81: 77-80.
50 McColl MD, Gibson BE. Sibling allogeneic bone marrow transplantation in a patient with type I Glanzmann’s thrombasthenia. Br J Haematol 1997; 99: 58-60.
51 Porta F, Forino C, De Martiis D. et al. Stem cell transplantation for primary immunodeficiencies. Bone Marrow Transplant 2008; 41 (Suppl. 02) S83-S86.
52 Levinsky RJ, Davies EG, Butler M. et al. Problems of mismatched bone marrow transplantation for severe combined immunodeficiency after soybean lectin fractionation. Birth Defects Orig Artic Ser 1983; 19: 147-150.
53 Hough R, Cooper N, Veys P. Allogeneic haemopoietic stem cell transplantation in children: what alternative donor should we choose when no matched sibling is available?. Br J Haematol 2009; 147: 593-613.
54 Filipovich AH, Stone JV, Tomany SC. et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome. Blood 2001; 97: 1598-1603.
55 Jaing TH, Chen SH, Tsai MH. et al. Transplantation of unrelated donor umbilical cord blood for nonmalignant diseases: a single institution’s experience with 45 patients. Biol Blood Marrow Transplant 2010; 16: 102-107.
56 Eyrich M, Lang P, Lal S. et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors. Br J Haematol 2001; 114: 422-432.
57 Gonzalez-Vicent M, Perez A, Abad L. et al. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients. J Pediatr Hematol Oncol 2010; 32: e85-e90.
58 Socie G, Henry-Amar M, Cosset JM. et al. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood 1991; 78: 277-279.
59 Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008; 22: 53-63.
60 Parkman R, Rappeport J, Camitta B. et al. Successful use of multiagent immunosuppression in the bone marrow transplantation of sensitized patients. Blood 1978; 52: 1163-1169.
61 Santos GW, Tutschka PJ, Brookmeyer R. et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
62 Slattery JT, Sanders JE, Buckner CD. et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
63 Gryn J, Zeigler ZR, Shadduck RK, Thomas C. Clearance of erythrocyte allo-antibodies using Rituximab. Bone Marrow Transplant 2002; 29: 631-632.
64 Salama A. Current treatment options for primary immune thrombocytopenia. Expert Rev Hematol 2011; 04: 107-118.
65 McCann SR, Lawler M. Mixed chimaerism; detection and significance following BMT. Bone Marrow Transplant 1993; 11: 91-94.
66 Bader P, Niethammer D, Willasch A. et al. How and when should we monitor chimerism after allogeneic stem cell transplantation?. Bone Marrow Transplant 2005; 35: 107-119.
67 Ortega M, Escudero T, Caballin MR. et al. Followup of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants. Bone Marrow Transplant 1999; 24: 81-87.
68 Lucarelli G, Galimberti M, Giardini C. et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann NY Acad Sci 1998; 850: 270-275.
69 Wilcox DA, Olsen JC, Ishizawa L. et al. Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc Natl Acad Sci USA 1999; 96: 9654-9659.
70 Fang J, Hodivala-Dilke K, Johnson BD. et al. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood 2005; 106: 2671-2679.
71 Fang J, Jensen ES, Boudreaux MK. et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci USA 2011; 108: 9583-9588.
72 Wilcox DA, White 2nd GC. Gene therapy for platelet disorders: studies with Glanzmann’s thrombasthenia. J Thromb Haemost 2003; 01: 2300-2311.